ATOSSA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ATOSSA THERAPEUTICS, INC. (ATOS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $926.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-11-13
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $926.00K, a 44.42% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $1.60M, a 9.49% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $1.57M, a 12.90% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $1.67M, a 7.13% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.79M, a 28.88% increase from fiscal 2021.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $5.27M, a 74.46% increase from fiscal 2020.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $3.02M, a 57.49% decline from fiscal 2019.
- ATOSSA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $7.10M, a 574.15% increase from fiscal 2018.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-09-30 | $926.00K 10-Q · filed 2023-11-13 | $2.53M derived: sum of 2 quarters · filed 2023-11-13 | $4.10M derived: sum of 3 quarters · filed 2023-11-13 | |||
| 2023-06-30 | $1.60M 10-Q · filed 2023-11-13 | $3.18M derived: sum of 2 quarters · filed 2023-11-13 | ||||
| 2023-03-31 | $1.57M 10-Q · filed 2023-11-13 | |||||
| 2022-12-31 | $6.79M 10-K · filed 2023-03-22 | |||||
| 2022-09-30 | $1.67M 10-Q · filed 2023-11-13 | $3.44M derived: sum of 2 quarters · filed 2023-11-13 | $5.24M derived: sum of 3 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $1.77M 10-Q · filed 2023-11-13 | $3.58M derived: sum of 2 quarters · filed 2023-11-13 | ||||
| 2022-03-31 | $1.81M 10-Q · filed 2023-11-13 | |||||
| 2021-12-31 | $5.27M 10-K · filed 2023-03-22 | |||||
| 2021-09-30 | $1.79M 10-Q · filed 2022-11-07 | $1.79M 10-Q · filed 2021-11-15 | $3.01M derived: sum of 2 quarters · filed 2022-11-07 | $3.65M derived: sum of 3 quarters · filed 2022-11-07 | ||
| 2021-06-30 | $1.21M 10-Q · filed 2022-11-07 | $1.21M 10-Q · filed 2021-08-13 | $1.85M derived: sum of 2 quarters · filed 2022-11-07 | |||
| 2021-03-31 | $640.00K 10-Q · filed 2022-11-07 | $639.75K 10-Q · filed 2021-05-14 | ||||
| 2020-12-31 | $3.02M 10-K · filed 2022-02-28 | $3.02M 10-K · filed 2021-03-31 | ||||
| 2020-09-30 | $663.59K 10-Q · filed 2021-11-15 | $1.70M derived: sum of 2 quarters · filed 2021-11-15 | $2.39M derived: sum of 3 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $1.04M 10-Q · filed 2021-11-15 | $1.72M derived: sum of 2 quarters · filed 2021-11-15 | ||||
| 2020-03-31 | $687.75K 10-Q · filed 2021-11-15 | |||||
| 2019-12-31 | $7.10M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $751.65K 10-Q · filed 2020-11-13 | $6.07M derived: sum of 2 quarters · filed 2020-11-13 | $6.35M derived: sum of 3 quarters · filed 2020-11-13 | $6.67M derived: sum of 4 quarters · filed 2020-11-13 | ||
| 2019-06-30 | $5.32M 10-Q · filed 2020-11-13 | $5.59M derived: sum of 2 quarters · filed 2020-11-13 | $5.92M derived: sum of 3 quarters · filed 2020-11-13 | $6.25M derived: sum of 4 quarters · filed 2020-11-13 | ||
| 2019-03-31 | $275.83K 10-Q · filed 2020-11-13 | $603.08K derived: sum of 2 quarters · filed 2020-11-13 | $935.14K derived: sum of 3 quarters · filed 2020-11-13 | $1.11M derived: sum of 4 quarters · filed 2020-11-13 | ||
| 2018-12-31 | $327.24K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $659.31K derived: sum of 2 quarters · filed 2020-03-26 | $838.36K derived: sum of 3 quarters · filed 2020-03-26 | $1.05M 10-K · filed 2020-03-26 | ||
| 2018-09-30 | $332.06K 10-Q · filed 2019-11-13 | $511.11K derived: sum of 2 quarters · filed 2019-11-13 | $726.25K 10-Q · filed 2018-11-14 | $952.43K derived: sum of 4 quarters · filed 2019-11-13 | ||
| 2018-06-30 | $179.05K 10-Q · filed 2019-11-13 | $394.19K 10-Q/A · filed 2018-11-13 | $620.37K derived: sum of 3 quarters · filed 2019-11-13 | $844.62K derived: sum of 4 quarters · filed 2019-11-13 | ||
| 2018-03-31 | $215.14K 10-Q · filed 2019-11-13 | $441.32K derived: sum of 2 quarters · filed 2019-11-13 | $665.57K derived: sum of 3 quarters · filed 2019-11-13 | |||
| 2017-12-31 | $226.18K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $450.44K derived: sum of 2 quarters · filed 2019-03-28 | $786.55K 10-K · filed 2019-03-28 | |||
| 2017-09-30 | $224.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $560.37K 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | $336.12K 10-Q · filed 2017-08-14 | |||||
| 2016-12-31 | $226.14K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-08 | $483.52K derived: sum of 2 quarters · filed 2018-03-08 | $876.19K 10-K · filed 2018-03-08 | |||
| 2016-09-30 | $257.39K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-03-21 | $650.05K 10-Q/A · filed 2017-03-21 | ||||
| 2016-06-30 | $392.66K 10-Q/A · filed 2017-03-21 | |||||
| 2015-12-31 | $894.66K 10-K/A · filed 2017-03-21 | |||||
| 2015-06-30 | $205.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $385.74K 10-Q · filed 2015-08-06 | $539.28K derived: sum of 3 quarters · filed 2016-03-30 | $686.68K derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2015-03-31 | $180.63K 10-Q · filed 2015-05-13 | $334.17K derived: sum of 2 quarters · filed 2016-03-30 | $481.57K derived: sum of 3 quarters · filed 2016-03-30 | |||
| 2014-12-31 | $153.54K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $300.94K derived: sum of 2 quarters · filed 2016-03-30 | $698.66K 10-K · filed 2016-03-30 | |||
| 2014-09-30 | $147.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $545.12K 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $397.71K 10-Q · filed 2014-08-12 | |||||
| 2013-12-31 | $1.44M 10-K · filed 2015-03-30 | |||||
| 2012-12-31 | $166.81K 10-K · filed 2014-03-27 | |||||
| 2011-12-31 | $140.06K 10-K · filed 2014-03-27 | |||||
| 2010-12-31 | $30.40K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |